scholarly article | Q13442814 |
P50 | author | Jonathan C Welti | Q58890564 |
Adam Sharp | Q62065516 | ||
P2093 | author name string | Johann S de Bono | |
Julian Blagg | |||
P2860 | cites work | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
The resurgence of covalent drugs | Q34174891 | ||
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer | Q34462138 | ||
Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes | Q36021859 | ||
An androgen receptor N-terminal domain antagonist for treating prostate cancer. | Q36966859 | ||
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects | Q38212470 | ||
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. | Q38769817 | ||
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer | Q38801131 | ||
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. | Q39819392 | ||
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer | Q41009606 | ||
Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding | Q46745891 | ||
P433 | issue | 17 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 4280-4282 | |
P577 | publication date | 2016-06-21 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer | |
P478 | volume | 22 |
Q58610787 | Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation |
Q90015708 | Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor |
Q64122891 | Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway |
Q55004240 | HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami |
Q55071360 | Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer. |
Q64940039 | Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. |
Q52659701 | New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. |
Q50230942 | Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. |
Q100316309 | Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors |
Q38729033 | Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells |
Q57105625 | Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer |
Search more.